QTX3034 in Patients With KRAS G12D Mutation
Public ClinicalTrials.gov record NCT06227377. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Study identification
- NCT ID
- NCT06227377
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Quanta Therapeutics
- Industry
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- Cetuximab Combination Product
- QTX3034 Drug
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2024
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
- Last update posted
- Apr 26, 2026
2024 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | Recruiting |
| Sarah Cannon Research Institute (SCRI) | Denver | Colorado | 80218 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06511 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10461 | Recruiting |
| Duke University | Durham | North Carolina | 27710 | Recruiting |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| SCRI- Nashville | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Recruiting |
| START San Antonio, LLC | San Antonio | Texas | 78229 | Recruiting |
| University of Utah, Huntsman Cancer Center | Salt Lake City | Utah | 84112 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06227377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06227377 live on ClinicalTrials.gov.